{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T21:07:58Z","timestamp":1785618478553,"version":"3.56.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rceng.2025.502330","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:51:13Z","timestamp":1751428273000},"page":"502330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccination in chronic obstructive pulmonary disease (COPD): Scientific evidence and strategies to reduce risks"],"prefix":"10.1016","volume":"225","author":[{"given":"\u00d3.","family":"Porto Fuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muela Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Alonso Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2025.502330_bib0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rceng.2025.502330_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2021.100097","article-title":"Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias [SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases]","volume":"3","author":"Villar-\u00c1lvarez","year":"2021","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.rceng.2025.502330_bib0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/resp.14331","article-title":"Vaccination in patients with COPD: COVID has raised the bar","volume":"27","author":"Waterer","year":"2022","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.rceng.2025.502330_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vacun.2023.04.005","article-title":"Vacunaci\u00f3n en el paciente respiratorio adulto, \u00bfbailamos? [Immunizing adult respiratory patients, shall we dance along?]","volume":"24","author":"Villar-\u00c1lvarez","year":"2023","journal-title":"Vacunas"},{"key":"10.1016\/j.rceng.2025.502330_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0034-2023","article-title":"The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus","volume":"32","author":"Simon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rceng.2025.502330_bib0030","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.011","article-title":"2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rceng.2025.502330_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccm.2013.11.001","article-title":"Acute COPD exacerbations","volume":"35","author":"Wedzicha","year":"2014","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/vaccines12020213","article-title":"Bacterial vaccinations in patients with chronic obstructive pulmonary disease","volume":"12","author":"Par\u00f3czai","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.eimc.2015.09.002","article-title":"Pneumococcal vaccines. New conjugate vaccines for adults","volume":"33","author":"Campins Mart\u00ed","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.rceng.2025.502330_bib0055","article-title":"Advances in development and application of influenza vaccines","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rceng.2025.502330_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices - United States, 2019","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12931-022-02305-1","article-title":"Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?","volume":"24","author":"Safonova","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.rceng.2025.502330_bib0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/COPD.S394101","article-title":"Efficacy of mRNA and inactivated whole virus vaccines against COVID-19 in patients with chronic respiratory diseases","volume":"18","author":"Kwok","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0075","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0080","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/jcm11051423","article-title":"Time trends (2012-2020), sex differences and predictors for influenza vaccination uptake among individuals with chronic obstructive pulmonary disease in Spain","volume":"11","author":"Fuentes-Alonso","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1129079","article-title":"COVID-19 vaccine hesitancy in Spain and associated factors","volume":"11","author":"Falcon","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.rceng.2025.502330_bib0090","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.29.1800446","article-title":"Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017","volume":"24","author":"Vila-C\u00f3rcoles","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.rceng.2025.502330_bib0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/vaccines11091422","article-title":"Poverty and influenza\/pneumococcus vaccinations in older people: data from the Survey of Health, Ageing and Retirement in Europe (SHARE) study","volume":"11","author":"Veronese","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/vaccines12010014","article-title":"Evaluating influenza vaccination practices among COPD patients","volume":"12","author":"Al-Qerem","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0105","first-page":"620","article-title":"Identification of barriers to influenza vaccination in patients with chronic obstructive pulmonary disease: analysis of the 2012 behavioral risk factors surveillance system","volume":"3","author":"Hsu","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0110","article-title":"Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease","volume":"1","author":"Walters","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rceng.2025.502330_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chest.2018.10.044","article-title":"Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD","volume":"155","author":"Mulpuru","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rceng.2025.502330_bib0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.37201\/req\/137.2023","article-title":"Importance of National Influenza Centers in the surveillance of highly pathogenic avian viruses. The time for One-Health is now","volume":"37","author":"Sanz-Mu\u00f1oz","year":"2024","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.rceng.2025.502330_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2022.100181","article-title":"Immunosenescence, immune fitness and vaccination schedule in the adult respiratory patient","volume":"4","author":"Villar-\u00c1lvarez","year":"2022","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.rceng.2025.502330_bib0130","article-title":"Immunosenescence, aging and successful aging","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.rceng.2025.502330_bib0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.chest.2018.09.003","article-title":"The aging lung: is lung health good health for older adults?","volume":"155","author":"Bowdish","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rceng.2025.502330_bib0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41541-021-00354-z","article-title":"Vaccination as a preventative measure contributing to immune fitness","volume":"6","author":"Laup\u00e8ze","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.rceng.2025.502330_bib0145","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.rceng.2025.502330_bib0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/antibiotics12010138","article-title":"Vaccination against community-acquired pneumonia in Spanish adults: practical recommendations by the NeumoExperts Prevention Group","volume":"12","author":"Redondo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95129-w","article-title":"Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study","volume":"11","author":"Ignatova","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101337","article-title":"Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"68","author":"Bao","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.rceng.2025.502330_bib0165","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report","year":"2025"},{"key":"10.1016\/j.rceng.2025.502330_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184877","article-title":"Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease","volume":"12","author":"Bornheimer","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.rceng.2025.502330_bib0175","article-title":"Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine","volume":"6","author":"Carniel","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.rceng.2025.502330_bib0180","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.15585\/mmwr.mm7029a1","article-title":"Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021","volume":"70","author":"Olsen","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0185","doi-asserted-by":"crossref","first-page":"00703","DOI":"10.1183\/23120541.00703-2022","article-title":"Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021","volume":"9","author":"Ankert","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rceng.2025.502330_bib0190","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0200","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0205","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.rceng.2025.502330_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0215","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the advisory committee on immunization practices - United States, 2024","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126310","article-title":"Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines","volume":"42","author":"King","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.rceng.2025.502330_bib0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","article-title":"Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations","volume":"41","author":"Ritchie","year":"2020","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0230","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/COPD.S306916","article-title":"Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease","volume":"16","author":"Jang","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0235","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1753465816646050","article-title":"Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness","volume":"10","author":"Sanei","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.7326\/L21-0018","article-title":"Acute cardiovascular events associated with influenza in hospitalized adults","volume":"174","author":"Chow","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0245","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurjpc\/zwac152","article-title":"Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis","volume":"29","author":"Jaiswal","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.rceng.2025.502330_bib0250","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"144","author":"Fr\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2025.502330_bib0255","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/vaccines11040753","article-title":"Cost-effectiveness of vaccination of older adults with an MF59\u00ae-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in Denmark, Norway, and Sweden","volume":"11","author":"Jacob","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0260","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.rceng.2025.502330_bib0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.rceng.2025.502330_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100789","article-title":"COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis","volume":"33","author":"Gerayeli","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rceng.2025.502330_bib0275","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00920-2021","article-title":"Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights","volume":"58","author":"Wark","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rceng.2025.502330_bib0280","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/infdis\/jiab619","article-title":"Effectiveness of mRNA vaccines against COVID-19 Hospitalization by age and chronic medical conditions burden among immunocompetent US adults, March-August 2021","volume":"225","author":"Lewis","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0285","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/vaccines11121786","article-title":"Waning of SARS-CoV-2 vaccine effectiveness in COPD patients: lessons from the delta variant","volume":"11","author":"Polivka","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.rceng.2025.502330_bib0290","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2286686","article-title":"Awareness of and attitude toward COVID-19 vaccination among individuals with COPD and the strategies to overcome vaccine hesitation: a mini review","volume":"19","author":"Liang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.rceng.2025.502330_bib0295","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae)","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.rceng.2025.502330_bib0305","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00497-2022","article-title":"Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects","volume":"60","author":"Southworth","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rceng.2025.502330_bib0310","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: Pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.rceng.2025.502330_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054445","article-title":"Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review","volume":"8","author":"Bloom-Feshbach","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rceng.2025.502330_bib0320","article-title":"Respiratory syncytial virus infection in adults","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.rceng.2025.502330_bib0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","article-title":"Respiratory syncytial virus infection: an illness for all ages","volume":"38","author":"Walsh","year":"2017","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.arbres.2024.01.004","article-title":"Respiratory syncytial virus vaccination recommendations for adults aged 60 years and older: the NeumoExperts Prevention Group position paper","volume":"60","author":"Redondo","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rceng.2025.502330_bib0335","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciad471","article-title":"Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions","volume":"78","author":"Feldman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0345","series-title":"P\u00f3ster presentado en el congreso CHEST 2024","article-title":"The efficacy of a single dose of the respiratory syncytial virus prefusion F protein vaccine in adults&60 years of age over 3 RSV seasons","author":"Ison","year":"2024"},{"key":"10.1016\/j.rceng.2025.502330_bib0350","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.rceng.2025.502330_bib0355","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/10600280241241049","article-title":"Vaccines for respiratory syncytial virus prevention in older adults","volume":"58","author":"Wroblewski","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rceng.2025.502330_bib0360","series-title":"INN-Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) \u2013 European Medicines Agency","year":"2023"},{"key":"10.1016\/j.rceng.2025.502330_bib0365","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2025.502330_bib0370","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","article-title":"Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0375","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"Evaluation of recombinant live-attenuated Respiratory Syncytial Virus (RSV) vaccines RSV\/\u0394NS2\/\u03941313\/I1314L and RSV\/276 in RSV-seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"J Infect Dis"},{"issue":"12 Suppl 2","key":"10.1016\/j.rceng.2025.502330_bib0380","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1093\/infdis\/jiaa469","article-title":"Pertussis (Whooping Cough)","volume":"224","author":"Decker","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0385","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.arbres.2021.06.008","article-title":"Whooping cough: the visible enemy","volume":"58","author":"Gonz\u00e1lez-Barcala","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rceng.2025.502330_bib0390","article-title":"Pertussis vaccine in COPD and asthma: an old acquaintance is back","volume":"4","author":"Villar-\u00c1lvarez","year":"2021","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.rceng.2025.502330_bib0395","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.chest.2023.12.020","article-title":"Increased burden of pertussis among adolescents and adults with asthma or COPD in the United States, 2007 to 2019","volume":"165","author":"Naeger","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rceng.2025.502330_bib0400","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2159731","article-title":"Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases","volume":"19","author":"Van den Steen","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.rceng.2025.502330_bib0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38355-8","article-title":"Immune response to pertussis vaccine in COPD patients","volume":"13","author":"Feredj","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.rceng.2025.502330_bib0410","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0415","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2025.502330_bib0420","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rceng.2025.502330_bib0425","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:00:08Z","timestamp":1762534808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887425000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2254887425000773"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2025.502330","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in chronic obstructive pulmonary disease (COPD): Scientific evidence and strategies to reduce risks","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2025.502330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2025.502330","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502330"}}